Fiona Marshall | |
|---|---|
&sq=Envato&lang=en&file=File:Fiona_Marshall_at_NIH%E2%80%99s_2017_Daly_lecture.jpg) Marshall speaking at the National Institutes of Health 2017 Daly lecture | |
| Born | Fiona Hamilton Marshall |
| Alma mater | University of Bath (BSc) University of Cambridge (PhD) |
| Scientific career | |
| Fields | Drug discovery GPCRs Neuroscience[1][2] |
| Institutions | Novartis Merck & Co. GlaxoSmithKline |
| Thesis | Cholecystokinin/dopamine interactions in the rat basal ganglia (1990) |
| Doctoral advisor | John Hughes |
Fiona Hamilton Marshall FRS FMedSci is a British pharmacologist, biotech-founder and President of Biomedical Research at Novartis.[3][2][4] She founded and previously served as Chief Scientific Officer at Heptares Therapeutics,[2] which was acquired by the Japanese biopharmaceutical company Sosei, where she served as Vice President.[1] She was elected Fellow of the Academy of Medical Sciences in 2016[5] and the Royal Society in 2021.[6]
- ^ a b Fiona Marshall publications indexed by Google Scholar
- ^ a b c Cite error: The named reference
epmcwas invoked but never defined (see the help page). - ^ Fishburn, C. Simone. "Reshaping research at Novartis". BioCentury. Retrieved 12 June 2024.
- ^ Carroll, John. "NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall". Endpoints News. Retrieved 1 September 2022.
- ^ "Dr Fiona Marshall | The Academy of Medical Sciences". acmedsci.ac.uk.
- ^ Cite error: The named reference
frswas invoked but never defined (see the help page).
